Evidence map›Paper›PMID 39929535›Full record

Trial reportBMJ global health2025

Effect of biannual azithromycin on respiratory pathogens among symptomatic children: results from the randomised Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) I trial.

Jie Liu, Stephanie A Brennhofer, Jixian Zhang, Suzanne Stroup, Suporn Pholwat, Ahmed M Arzika, Ramatou Maliki, Amza Abdou, Elodie Lebas, Kieran S O'Brien and 6 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMJ global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02048007 (Evaluating Impact of Azithromycin Mass Drug Administrations on All-cause Mortality and Antibiotic Resistance), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02048007 phase4completednot on this map

Evaluating Impact of Azithromycin Mass Drug Administrations on All-cause Mortality and Antibiotic Resistance: Morbidity Study

TypeinterventionalSponsorUniversity of California, San FranciscoRan2014 to 2020Enrolled72,000ConditionsChildhood MortalityArmsAzithromycin, Placebo
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jie LiuSchool of Public Health, Qingdao University, Qingdao, Shandong, China.
Stephanie A BrennhoferDivision of Infectious Diseases & International Health, University of Virginia School of Medicine, Charlottesville, Virginia, USA.ORCID http://orcid.org/0000-0002-9914-4471
Jixian ZhangDivision of Infectious Diseases & International Health, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Suzanne StroupDivision of Infectious Diseases & International Health, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Suporn PholwatDivision of Infectious Diseases & International Health, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Ahmed M ArzikaCentre de Recherche et Interventions en Sante Publique, Niamey, Niger.
Ramatou MalikiCarter Center, Niamey, Niger.
Amza AbdouProgramme Nationale de Santé Oculaire, Niamey, Niger.
Elodie LebasFrancis I Proctor Foundation, University of California San Francisco, San Francisco, California, USA.
Kieran S O'BrienFrancis I Proctor Foundation, University of California San Francisco, San Francisco, California, USA.ORCID http://orcid.org/0000-0002-1962-5321
Benjamin F ArnoldFrancis I Proctor Foundation, University of California San Francisco, San Francisco, California, USA.
Jeremy D KeenanFrancis I Proctor Foundation, University of California San Francisco, San Francisco, California, USA.ORCID http://orcid.org/0000-0002-7118-1457
Thomas M LietmanFrancis I Proctor Foundation, University of California San Francisco, San Francisco, California, USA.
James A Platts-MillsDivision of Infectious Diseases & International Health, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Elizabeth T Rogawski McQuadeDepartment of Epidemiology, Emory University, Atlanta, Georgia, USA.
Eric R HouptDivision of Infectious Diseases & International Health, University of Virginia School of Medicine, Charlottesville, Virginia, USA erh6k@virginia.edu.ORCID http://orcid.org/0000-0003-1085-1354

Funding

Gates Foundation INV-008606
6 · The paper itself

Abstract

introductionBiannual (ie, every 6 months) mass drug administration of azithromycin has reduced childhood mortality in Niger, but its effects on specific respiratory pathogens are not fully elucidated.

methodsAcross 2 years of the Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) study in Niger, we evaluated 1468 nasopharyngeal swabs from children who presented for care with respiratory symptoms. Swabs were tested by quantitative PCR using a customised TaqMan Array Card that included assays for 19 respiratory pathogens.

resultsNasopharyngeal detection of

conclusionsBiannual administration of azithromycin to communities in Niger was associated with lower prevalence of TRIAL REGISTRATION NUMBER: NCT02048007.

Indexed as

Anti-Bacterial AgentsAzithromycinRespiratory Tract InfectionsBordetella pertussisChildChild, PreschoolFemaleHaemophilus influenzaeHumansInfantMacrolidesMaleMass Drug AdministrationMoraxella catarrhalisNasopharynxNigerAnti-Bacterial AgentsAzithromycinMacrolidesPertussisPneumonia

Identifiers

PMID39929535
PMCPMC11815404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.